MYSTERIOUS: Axsome therapeutics - What They Never Told You

Axsome Therapeutics Readies Auvelity Alzheimer’s Agitation Launch, Expands CNS Pipeline

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing to launch Auvelity in Alzheimer’s disease agitation this month while continuing to expand the drug’s use in major depressive disorder and advance a broad central nervous system pipeline. Speaking at a Jefferies fireside chat

MarketBeat · Jun 6

Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing for a June launch of AUVELITY in Alzheimer’s disease agitation while continuing to expand its push in major depressive disorder, citing broad payer access, a larger sales force and what they described as a differentiated clin

MarketBeat · May 12

Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) reported better-than-expected second-quarter financial results on Monday.

Benzinga · Aug 5, 2025